Goldman Sachs analyst Rajan Sharma has reiterated their bullish stance on CATX stock, giving a Buy rating on February 12.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rajan Sharma has given his Buy rating due to a combination of factors that, in his view, create an attractive risk‑reward profile for Perspective Therapeutics (CATX). He highlights the company’s differentiated radiopharmaceutical platform, which targets significant unmet medical needs and positions CATX to participate in a growing niche within oncology treatment.
Sharma also points to a solid clinical and regulatory roadmap, with upcoming milestones that could serve as catalysts for the share price, alongside a balance sheet he views as sufficient to fund key development steps. In addition, he sees the current valuation as not fully reflecting CATX’s long‑term revenue and margin potential, supporting his view that the stock offers meaningful upside from current levels.
According to TipRanks, Sharma is a 3-star analyst with an average return of 2.7% and a 58.06% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, UCB SA, and Perspective Therapeutics.
In another report released on February 12, JonesTrading also maintained a Buy rating on the stock with a $18.00 price target.